BioLife Solutions Inc. Announces 2023 Annual Meeting Results

Strategic Insights -

At the 2023 annual meeting of BioLife Solutions Inc., held on July 21, 2023, the company's stockholders voted in favor of several key proposals, including the re-election of seven directors and the approval of the compensation of the company's named executive officers. The meeting also saw the ratification of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023, and the approval of the 2023 Omnibus Performance Incentive Plan.

Key Takeaways:

  • The number of shares of common stock entitled to vote at the Annual Meeting was 43,486,857, with 38,106,169 shares present or represented by valid proxy.
  • Seven directors, including Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, Rachel Ellingson, Roderick de Greef, and Timothy Moore, were re-elected to serve until the 2024 annual meeting of stockholders.
  • The compensation for the company's named executive officers was approved by a non-binding advisory vote, with 28,011,724 votes in favor and 5,972,831 votes against.
  • The appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified with 38,080,800 votes in favor and 10,622 votes against.
  • The 2023 Omnibus Performance Incentive Plan was approved with 32,018,463 votes in favor and 1,961,503 votes against.
  • Rachel Ellingson received the lowest number of "for" votes among the directors, with 18,381,609 votes in her favor.
  • Roderick de Greef received the highest number of "for" votes among the directors with 33,938,015 votes in his favor.

Statistics:

  • 43,486,857 shares of common stock were entitled to vote at the Annual Meeting.
  • 38,106,169 shares were present or represented by valid proxy.
  • 33,114,623 shares voted in favor of director Michael Rice.
  • 33,851,097 shares voted in favor of director Timothy Moore.
  • 33,938,015 shares voted in favor of director Roderick de Greef.

Sources:

  • United States Securities and Exchange Commission
  • BioLife Solutions, Inc. (Exact name of registrant as specified in its charter)
  • Section 13 or 15(d) of the Securities Exchange Act of 1934